Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line
information fournie par Boursorama CP 08/09/2026 à 07:30
Ajouter Boursorama à vos sources

Strasbourg (France), Berlin (Germany), September 8, 2026, 7:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a leading contract development and manufacturing organization (CDMO) in biologics, vaccines and viral vectors, today announce that the companies have broadened the scope of their existing collaboration. Transgene’s additional license agreement for ProBioGen’s AGE1.CR.pIX® suspension cell line aims to enhance Transgene’s manufacturing capabilities with this specialized production technology.

ProBioGen’s AGE1.CR.pIX® suspension cell line platform for vaccine production enables highly efficient manufacturing processes, supporting reliable, cost-effective production and increased productivity. The continued partnership between Transgene and ProBioGen underscores a shared commitment to advancing vaccine innovations through manufacturing scalability and optimization support.

.../...

Valeurs associées

TRANSGENE
0,8540 EUR Euronext Paris -0,12%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
98,83 +0,28%
CAC 40
8 154,91 +0,20%
Or
4 338,2 -0,40%
EUR/USD SPOT
1,14367 -0,12%
TOTALENERGIES
78,15 -0,52%
Chargement...

Pages les plus populaires

L'offre BoursoBank